Can-Fite BioPharma American Depositary Shares
CANF
9 hedge funds and large institutions have $536K invested in Can-Fite BioPharma American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.
1,119% more capital inflows, than outflows
Capital inflows: $406K | Capital outflows: $33.3K
2.38% more ownership
Funds ownership: 1.66% → 4.03% (+2.4%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$332K |
| 2 |
Schechter Investment Advisors
Birmingham,
Michigan
|
+$43.2K |
| 3 |
Morgan Stanley
New York
|
+$28.5K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.2K |
| 5 |
Stone House Investment Management
Tunkhannock,
Pennsylvania
|
+$1.03K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.9K |
| 2 |
JP Morgan Chase
New York
|
-$1.22K |
| 3 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$140 |
CANF Hedge Fund Activity: Q4 2023 in Review
9 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2023, worth a combined $536K — up 199% from $179K a quarter earlier.
Fund positioning in CANF was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $332K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $31.9K sold.
- 9 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $536K of Can-Fite BioPharma American Depositary Shares stock for Q4 2023, up 199% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2023 was Armistice Capital, an estimated $332K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2023 was Susquehanna International Group, an estimated $31.9K sold.
Based on aggregated 13F filings for Q4 2023.